Abdominal Manifestations of Neuroendocrine Tumors

Abstract

Despite being rare, the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (NETs) is rising. They are a heterogeneous group of tumors with differences in clinical presentations, genetics, and imaging features. Advances in pathological classification, imaging (including recent radiotracer approval for functional imaging in the Unites States), and therapy have impacted management of these tumors. It is important in the multidisciplinary approach to patient care to be familiar with the tumor biology, imaging techniques for diagnosis and staging, and therapeutic options. This article will discuss these new developments, particularly focusing on pancreatic and small bowel NETs.

Keywords

gastroenteropancreatic neuroendocrine tumors - PNETs - NETs

• References

• 1 Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39 (06) 707-712
• 2 Yao JC, Hassan M, Phan A. , et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
• 3 Dasari A, Shen C, Halperin D. , et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3 (10) 1335-1342
• 4 Halperin DM, Kulke MH, Yao JC. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med 2015; 66: 1-16
• 5 Bosman FT, Carneiro F, Hruban RH, Theise ND. , World Health Organization. International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010
• 6 Klöppel G, Klimstra DS, Hruban RH. , et al. Pancreatic neuroendocrine tumors: update on the new World Health Organization classification. AJSP: Reviews & Reports 2017; 22 (05) 233-239
• 7 Nakakura EK. Challenges staging neuroendocrine tumors of the pancreas, jejunum and ileum, and appendix. Ann Surg Oncol 2018; 25 (03) 591-593
• 8 Amin MB, Greene FL, Edge SB. , et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67 (02) 93-99
• 9 Luo G, Javed A, Strosberg JR. , et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol 2017; 35 (03) 274-280
• 10 Mittra ES. Neuroendocrine tumor therapy: ¹⁷⁷Lu-DOTATATE. AJR Am J Roentgenol 2018; 211 (02) 278-285
• 11 Krenning EP, Bakker WH, Breeman WA. , et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1 (8632): 242-244
• 12 Krenning EP, Bakker WH, Kooij PP. , et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33 (05) 652-658
• 13 Olsen JO, Pozderac RV, Hinkle G. , et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995; 25 (03) 251-261
• 14 Balon HR. Updated practice guideline for somatostatin receptor scintigraphy. J Nucl Med 2011; 52 (12) 1838
• 15 Krenning EP, Kwekkeboom DJ, Bakker WH. , et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20 (08) 716-731
• 16 Gabriel M, Decristoforo C, Kendler D. , et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48 (04) 508-518
• 17 Deppen SA, Blume J, Bobbey AJ. , et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med 2016; 57 (06) 872-878
• 18 Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015; 35 (02) 500-516
• 19 Shastry M, Kayani I, Wild D. , et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 2010; 31 (12) 1025-1032
• 20 Binderup T, Knigge U, Loft A. , et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010; 51 (05) 704-712
• 21 Strosberg J, Krenning E. 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (14) 1391-1392
• 22 Shah MH, Goldner WS, Halfdanarson TR. , et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 2018; 16 (06) 693-702
• 23 Kazmierczak PM, Rominger A, Wenter V. , et al. The added value of ⁶⁸Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin. Eur Radiol 2017; 27 (04) 1676-1684
• 24 Haug AR, Cindea-Drimus R, Auernhammer CJ. , et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 2012; 53 (11) 1686-1692
• 25 Howe JR, Cardona K, Fraker DL. , et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas 2017; 46 (06) 715-731
• 26 Hope TA, Bergsland EK, Bozkurt MF. , et al. Appropriate use criteria for somatostatin receptor pet imaging in neuroendocrine tumors. J Nucl Med 2018; 59 (01) 66-74
• 27 Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19 (10) 1727-1733
• 28 Sahani DV, Bonaffini PA, Fernández-Del Castillo C, Blake MA. Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. Radiology 2013; 266 (01) 38-61
• 29 Dromain C, Déandréis D, Scoazec JY. , et al. Imaging of neuroendocrine tumors of the pancreas. Diagn Interv Imaging 2016; 97 (12) 1241-1257
• 30 van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol 2014; 10 (02) 102-114
• 31 Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI. Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol 2016; 26 (05) 1338-1347
• 32 Ichikawa T, Peterson MS, Federle MP. , et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000; 216 (01) 163-171
• 33 Sotoudehmanesh R, Hedayat A, Shirazian N. , et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 2007; 31 (03) 238-241
• 34 Gouya H, Vignaux O, Augui J. , et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 2003; 181 (04) 987-992
• 35 Khashab MA, Yong E, Lennon AM. , et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73 (04) 691-696
• 36 Marcos HB, Libutti SK, Alexander HR. , et al. Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology 2002; 225 (03) 751-758
• 37 Lewis RB, Lattin Jr GE, Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 2010; 30 (06) 1445-1464
• 38 Rodallec M, Vilgrain V, Couvelard A. , et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 2006; 6 (1-2): 77-85
• 39 Procacci C, Carbognin G, Accordini S. , et al. Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol 2001; 11 (07) 1175-1183
• 40 Manfredi R, Bonatti M, Mantovani W. , et al. Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour. Eur Radiol 2013; 23 (11) 3029-3039
• 41 Humphrey PE, Alessandrino F, Bellizzi AM, Mortele KJ. Non-hyperfunctioning pancreatic endocrine tumors: multimodality imaging features with histopathological correlation. Abdom Imaging 2015; 40 (07) 2398-2410
• 42 Bordeianou L, Vagefi PA, Sahani D. , et al. Cystic pancreatic endocrine neoplasms: a distinct tumor type?. J Am Coll Surg 2008; 206 (06) 1154-1158
• 43 Balachandran A, Tamm EP, Bhosale PR. , et al. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol 2012; 199 (03) 602-608
• 44 Raman SP, Hruban RH, Cameron JL, Wolfgang CL, Fishman EK. Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics. AJR Am J Roentgenol 2012; 199 (02) 309-318
• 45 Jang KM, Kim SH, Song KD, Kim YK, Lee SJ, Choi D. Differentiation of solid-type serous cystic neoplasm from neuroendocrine tumour in the pancreas: value of abdominal MRI with diffusion-weighted imaging in comparison with MDCT. Clin Radiol 2015; 70 (02) 153-160
• 46 Jeon SK, Lee JM, Joo I. , et al. Nonhypervascular pancreatic neuroendocrine tumors: differential diagnosis from pancreatic ductal adenocarcinomas at MR imaging-retrospective cross-sectional study. Radiology 2017; 284 (01) 77-87
• 47 Yamada S, Fujii T, Suzuki K. , et al. Preoperative identification of a prognostic factor for pancreatic neuroendocrine tumors using multiphase contrast-enhanced computed tomography. Pancreas 2016; 45 (02) 198-203
• 48 Bettini R, Partelli S, Boninsegna L. , et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011; 150 (01) 75-82
• 49 Takumi K, Fukukura Y, Higashi M. , et al. Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur J Radiol 2015; 84 (08) 1436-1443
• 50 Marion-Audibert AM, Barel C, Gouysse G. , et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003; 125 (04) 1094-1104
• 51 Boudreaux JP, Klimstra DS, Hassan MM. , et al; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010; 39 (06) 753-766
• 52 Woodbridge LR, Murtagh BM, Yu DF, Planche KL. Midgut neuroendocrine tumors: imaging assessment for surgical resection. Radiographics 2014; 34 (02) 413-426
• 53 Norlén O, Stålberg P, Öberg K. , et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 2012; 36 (06) 1419-1431
• 54 Makridis C, Rastad J, Oberg K, Akerström G. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 1996; 20 (07) 900-906 , discussion 907
• 55 Partelli S, Gaujoux S, Boninsegna L. , et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg 2013; 148 (10) 932-939
• 56 Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139 (12) 2679-2686
• 57 Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006; 17 (08) 1235-1249 , quiz 1250
• 58 Touzios JG, Kiely JM, Pitt SC. , et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg 2005; 241 (05) 776-783 , discussion 783–785
• 59 Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol 2012; 2012: 973946
• 60 Scharf M, Petry V, Daniel H, Rinke A, Gress TM. Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance. Neuroendocrinology 2018; 106 (01) 30-37
• 61 Elias D, Lefevre JH, Duvillard P. , et al. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg 2010; 251 (02) 307-310
• 62 Loyer EM, Chin H, DuBrow RA, David CL, Eftekhari F, Charnsangavej C. Hepatocellular carcinoma and intrahepatic peripheral cholangiocarcinoma: enhancement patterns with quadruple phase helical CT--a comparative study. Radiology 1999; 212 (03) 866-875
• 63 Denecke T, Baur AD, Ihm C. , et al. Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors. Eur J Radiol 2013; 82 (10) e550-e555
• 64 Eisenhauer EA, Therasse P, Bogaerts J. , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
• 65 Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13 (Suppl. 02) 4-7
• 66 de Mestier L, Dromain C, d'Assignies G. , et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer 2014; 21 (03) R105-R120
• 67 Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, Mansmann UR. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 2015; 51 (14) 1927-1936
• 68 Strosberg J, El-Haddad G, Wolin E. , et al; NETTER-1 Trial Investigators. Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
• 69 Enzler T, Fojo T. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. Semin Oncol 2017; 44 (02) 141-156
• 70 Krug S, Gress TM, Michl P, Rinke A. The role of cytotoxic chemotherapy in advanced pancreatic neuroendocrine tumors. Digestion 2017; 96 (02) 67-75
• 71 Chun YS, Vauthey JN, Boonsirikamchai P. , et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302 (21) 2338-2344
• 72 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60
• 73 Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010; 194 (06) 1470-1478
• 74 Faivre S, Ronot M, Dreyer C. , et al. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Target Oncol 2012; 7 (02) 127-133
• 75 Joo I, Kim HC, Kim GM, Paeng JC. Imaging evaluation following ⁹⁰Y radioembolization of liver tumors: what radiologists should know. Korean J Radiol 2018; 19 (02) 209-222
• 76 Atassi B, Bangash AK, Bahrani A. , et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 2008; 28 (01) 81-99
• 77 Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A. , et al; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015; 34 (04) 823-842
• 78 Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM. The status of neuroendocrine tumor imaging: from darkness to light?. Neuroendocrinology 2015; 101 (01) 1-17
• 79 Ng CS, Wei W, Duran C. , et al. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents. Abdom Radiol (NY) 2018; 43 (07) 1661-1669
• 80 Haug AR, Rominger A, Mustafa M. , et al. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011; 52 (11) 1679-1683
• 81 Yedururi S, Terpenning S, Gupta S. , et al. Radiofrequency ablation of hepatic tumor: subjective assessment of the perilesional vascular network on contrast-enhanced computed tomography before and after ablation can reliably predict the risk of local recurrence. J Comput Assist Tomogr 2017; 41 (04) 607-613